Literature DB >> 23429626

Surgical outcomes of superior versus inferior glaucoma drainage device implantation.

Amy Z Martino1, Shawn Iverson, William J Feuer, David S Greenfield.   

Abstract

PURPOSE: To compare the safety and intraocular pressure (IOP) lowering efficacy of initial glaucoma drainage device (GDD) implantation performed at the superior versus inferior limbus.
METHODS: A retrospective chart review was conducted to identify patients with glaucoma who had undergone initial Baerveldt GDD surgery at the inferior limbus for uncontrolled IOP. All eyes of patients had a minimum of 6 months of postoperative follow-up. These eyes were frequency-matched to eyes with initial Baerveldt GDD implantation performed at the superior limbus, within 5 years of age and 6 months of follow-up. Baseline demographic and clinical information, as well as preoperative and postoperative IOP, visual acuity, and number of antiglaucoma medications were extracted. Failure was defined as IOP>21 mm Hg or not reduced by 20% below baseline on 2 consecutive follow-up visits after 3 months, IOP≤5 mm Hg on 2 consecutive follow-up visits after 3 months, reoperation for glaucoma, or loss of light perception vision. Statistical methods consisted of Student t tests, χ test, and Kaplan-Meier time to failure analysis.
RESULTS: Fifty eyes (17 inferior, 33 superior) of 43 patients were enrolled. Mean postoperative follow-up in both groups were similar (mean 26.2±15.2 mo for inferior and 23.9±10.43 mo for superior, P=0.54). Trabeculectomy had been performed previously in 8/17 (47%) and 11/33 (33%) eyes (P=0.34) with inferior and superior implants, respectively. Mean preoperative IOP (mm Hg) in the superior group (26±11) was significantly higher (P=0.02) when compared with the inferior group (21±7). Success rates were similar (P>0.05) between the inferior and superior GDD groups during the study period, with 64.7% and 75.8% classified as successful at 1-year of follow-up and 43.1% and 65.7% at 2 years of follow-up, respectively. There was no difference in cumulative proportions of eyes failing between the groups (P=0.20, log-rank test). The mean postoperative IOP and number of antiglaucoma medications were similar (all P>0.05) in both groups during the first 2 years of postoperative follow-up. The frequency and types of postoperative complications in both the groups were similar. The 36-month cumulative reoperation rates for IOP control were 33.8% and 9.1%, respectively, in the inferior and superior GDD groups (P=0.04 log-rank test).
CONCLUSIONS: No differences were observed in the overall success rates of initial GDD implantation performed at the superior and inferior limbus in this cohort. However, inferior GDD implantation was associated with a greater incidence of reoperation for IOP control.

Entities:  

Mesh:

Year:  2015        PMID: 23429626      PMCID: PMC3677043          DOI: 10.1097/IJG.0b013e318287ac8f

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  15 in total

1.  Ahmed glaucoma valve implant vs trabeculectomy in the surgical treatment of glaucoma: a randomized clinical trial.

Authors:  M R Wilson; U Mendis; S D Smith; A Paliwal
Journal:  Am J Ophthalmol       Date:  2000-09       Impact factor: 5.258

Review 2.  Current management of glaucoma.

Authors:  Kenneth Schwartz; Donald Budenz
Journal:  Curr Opin Ophthalmol       Date:  2004-04       Impact factor: 3.761

3.  Inferonasal placement of aqueous shunts.

Authors:  Paul A Sidoti
Journal:  J Glaucoma       Date:  2004-12       Impact factor: 2.503

4.  Intermediate-term outcomes of 350-mm(2) Baerveldt glaucoma implants.

Authors:  R Krishna; D G Godfrey; D L Budenz; E Escalona-Camaaño; S J Gedde; D S Greenfield; W Feuer; I U Scott
Journal:  Ophthalmology       Date:  2001-03       Impact factor: 12.079

5.  New implant for drainage in glaucoma. Clinical trial.

Authors:  A C Molteno
Journal:  Br J Ophthalmol       Date:  1969-09       Impact factor: 4.638

6.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Authors:  Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2002-06

7.  The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma: a single-surgeon comparison of outcome.

Authors:  James C Tsai; Cameron C Johnson; Mary S Dietrich
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

8.  Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study.

Authors:  Kouros Nouri-Mahdavi; Douglas Hoffman; Anne L Coleman; Gang Liu; Gang Li; Douglas Gaasterland; Joseph Caprioli
Journal:  Ophthalmology       Date:  2004-09       Impact factor: 12.079

9.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

10.  Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.

Authors:  M Cristina Leske; Anders Heijl; Mohamed Hussein; Bo Bengtsson; Leslie Hyman; Eugene Komaroff
Journal:  Arch Ophthalmol       Date:  2003-01
View more
  2 in total

Review 1.  Aqueous shunts for glaucoma.

Authors:  Victoria L Tseng; Anne L Coleman; Melinda Y Chang; Joseph Caprioli
Journal:  Cochrane Database Syst Rev       Date:  2017-07-28

2.  Outcomes of XEN Gel Stent Implantation in the Inferonasal Quadrant after Failed Trabeculectomy.

Authors:  Eyüp Düzgün; Ali Olgun; Murat Karapapak; Abdurrahman Alpaslan Alkan; Melih Ustaoğlu
Journal:  J Curr Glaucoma Pract       Date:  2021 May-Aug
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.